Efficacy and Safety of Standard Triple Therapy for Helicobacter pylori Eradication in Latin America

Author:

Díaz-Rodríguez Dahiana M.1ORCID,Bustamante-Rengifo Javier A.12ORCID,García-Perdomo Herney A.3

Affiliation:

1. Group of Biotechnology and Bacterial Infections, Department of Microbiology, Cali, Colombia

2. Department of Nutrition and Dietetics, IU Escuela Nacional del Deporte, Cali, Colombia

3. Department of Surgery, Division of Urology/Uro-Oncology, School of Medicine, Universidad del Valle, Cali, Colombia

Abstract

Goals: To evaluate the efficacy and safety of standard triple therapy (STT) in Latin America. Background: Helicobacter pylori infection affects more than 50% of the Latin Americans and leads to gastric mucosa damage. Scarce data on effective therapeutic approaches in the region underscores the need for comprehensive information. Study: The analysis included Randomized Controlled Trials published up to the year 2020, comparing STT with other treatments. Cumulative relative risks (RR) were estimated, with 95% CI, according to intention-to-treat (ITT) and per protocol (PP) analysis. Results: Eleven studies (clinical trials conducted between 1995 and 2013), revealed cumulative eradication rates of 78.31–90.63% (ITT) and 76.71–93.55% (PP). The eradication with the STT was superior to sequential therapy (ITT—RR: 10.6, 95% CI: 1.01 to 1.12) (PP—RR: 10.6, 95% CI: 1.02-1.11) and dual therapy (ITT—RR: 1.61, 95% CI: 1.13-2.30) (PP—RR: 1.72, 95% CI: 1.25-2.37), but is less effective than other triple therapies (PP—RR: 0.85, 95% CI: 0.78-092). Regarding adverse effects, diarrhea, metallic taste, nausea, vomiting, and headache were the most common symptoms across treatments. Abdominal pain was associated with STT (ITT—RR: 1.75, 95% CI: 1.07-2.86). Conclusion: STT was a safe regimen but with acceptable efficacy (most eradication rates <90%). Due to rising clarithromycin resistance, the study suggests avoiding STT as a first-line treatment. These results must be considered with caution due to the low representativeness of several Latin American countries and the lack of recent high-quality randomized studies.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Reference44 articles.

1. Clinical management of Helicobacter pylori: the Latin American perspective;Coelho;Dig Dis,2014

2. Helicobacter pylori therapy: a paradigm shift;Graham;Expert Rev Anti-infective Ther,2016

3. Helicobacter pylori related health problems in children;Akcam;Iran J Public Health,2015

4. World gastroenterology organisation global guideline: Helicobacter pylori in developing countries;Hunt;J Gastrointestin Liver Dis,2011

5. The effect of antibiotic resistance on Helicobacter pylori eradication efficacy: a systematic review and meta-analysis;Zou;Helicobacter,2020

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3